A Phase 3 interventional study of denosumab and placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 10 sites in Korea, Republic of. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-05-07.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 20th largest by enrollment, is the only one that started in 2011, is one of 17 in phase 3, and was the 11th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 60 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
Drug: denosumab
placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
Drug: placebo
open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
Drug: open-label denosumab
double-blind phase: 60mg subcutaneous injection, single dose
double-blind phase: placebo subcutaneous injection, single dose
open-label phase: 60mg subcutaneous injection, single dose
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.
Time frame: Baseline and Month 6
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 1
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1 - measure at Baseline) divided by the measure at Baseline \* 100.
Time frame: Baseline and Month 1
Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 1 and Month 6
Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covarience (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1/6 - measure at Baseline) divided by the measure at Baseline \* 100.
Time frame: Baseline, Month 1 and Month 6
Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Months 1, 3 and 6
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.
Time frame: Baseline, Months 1, 3 and 6
Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From Baseline up to Month 6
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Hematocrit at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Mean Corpuscular Volume at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Red Blood Cell Count at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Red Cell Distribution Width at Month 6
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 6
Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab
Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 6 was summarized.
Time frame: Month 6
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.
Time frame: Baseline and Month 12
Mean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo
Mean percent change from Month 6 in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.
Time frame: Month 6 and Month 12
Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Denosumab
Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.
Time frame: Baseline and Month 12
Mean Percent Change From Month 6 in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Placebo
Mean percent change from Month 6 in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.
Time frame: Month 6 and Month 12
Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Denosumab
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.
Time frame: Baseline and Month 12
Median Percent Change From Month 6 in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Placebo
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by measure at Month 6 \* 100.
Time frame: Month 6 and Month 12
Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE) During the Open-Label Extension Phase
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From Month 6 to Month 12
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Hematocrit at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Mean Corpuscle Hemoglobin at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Red Blood Cell Count at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Change From Baseline in Red Cell Distribution Width at Month 12
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 12
Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 12 value minus the Baseline value.
Time frame: Baseline and Month 12
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 12
Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 12 was summarized.
Time frame: Month 12
| Milestone | Denosumab 60 mg | Placebo | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|---|---|
| Started | 69 | 66 | 0 | 0 |
| Completed the 6 month assessment | 62 | 64 | 0 | 0 |
| Completed | 60 | 63 | 0 | 0 |
| Not completed | 9 | 3 | 0 | 0 |
| Withdrew: Continuation criteria not met | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 | 0 | 0 |
| Milestone | Denosumab 60 mg | Placebo | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 60 | 63 |
| Completed | 0 | 0 | 58 | 61 |
| Not completed | 0 | 0 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.
| Percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6 | 4.10 ± 0.407 | 0.89 ± 0.413 |
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1 - measure at Baseline) divided by the measure at Baseline \* 100.
| Percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Lumbar Spine BMD at Month 1 | 1.35 ± 0.375 | 0.62 ± 0.380 |
Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covarience (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1/6 - measure at Baseline) divided by the measure at Baseline \* 100.
| Percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| Total hip, Month 1, n=67, 63 | 0.74 ± 0.238 | 0.05 ± 0.245 |
| Total hip, Month 6, n=69, 64 | 2.23 ± 0.245 | 0.57 ± 0.254 |
| Femoral neck, Month 1, n=67, 63 | 1.30 ± 0.344 | -0.04 ± 0.354 |
| Fermoral neck, Month 6, n=69, 64 | 2.23 ± 0.330 | 0.84 ± 0.343 |
| Trochanter, Month 1, n=67, 63 | 0.82 ± 0.380 | 0.39 ± 0.392 |
| Trochanter, Month n =69, 64 | 2.66 ± 0.418 | 0.67 ± 0.434 |
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.
| Percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| s-CTx, Month 1, n=69, 66 | -80.72 (-88.62 to -73.50) | -14.48 (-33.58 to -1.08) |
| s-CTx, Month 3, n=68, 65 | -82.23 (-89.00 to -73.67) | -27.49 (-44.85 to -5.13) |
| s-CTx, Month 6, n=60, 63 | -74.32 (-84.09 to -65.33) | -21.21 (-37.41 to 3.44) |
| s-PINP, Month 1, n=69, 66 | -18.75 (-35.71 to -6.00) | -4.65 (-17.86 to 9.68) |
| s-PINP, Month 3, n=68, 65 | -77.1 (-83.54 to -68.57) | -21.57 (-38.89 to -6.35) |
| s-PINP, Month 6, n=60, 63 | -76.18 (-81.27 to -61.89) | -21.05 (-42.42 to -6.67) |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
| Participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Any AE | 38 | 32 |
| Any SAE | 7 | 2 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Ratio | Denosumab 60 mg | Placebo |
|---|---|---|
| Albumin/globulin ratio, n=60, 63 | 0.020 ± 0.1424 | 0.052 ± 0.1390 |
| BUN/creatinine ratio, n=60, 63 | -7.917 ± 25.2917 | -4.063 ± 27.3436 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Grams (G)/Liter (L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Albumin, n=60,63 | 0.217 ± 1.8964 | 0.365 ± 2.2598 |
| Hemoglobin, n=59, 63 | 1.153 ± 5.8274 | 1.778 ± 5.6894 |
| Mean corpuscle hemoglobin concentration, n=59, 63 | -5.186 ± 9.9264 | -6.857 ± 9.4593 |
| Total protein, n=60, 63 | -0.050 ± 2.9939 | -0.127 ± 3.3864 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Internationational Units(IU)/Liter (L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Alkaline phosphatase, n=60, 63 | -24.283 ± 15.9513 | -8.222 ± 11.2127 |
| Alanine amino transferase, n=60, 63 | 2.117 ± 6.4047 | -0.397 ± 8.8035 |
| Aspartate amino transferase, n=59, 63 | 1.034 ± 4.4527 | -0.032 ± 7.4962 |
| Creatine kinase, n=60, 63 | 7.617 ± 51.6658 | 3.905 ± 31.2052 |
| Gamma glutamyl transferase, n=60, 63 | -0.133 ± 8.4381 | -2.143 ± 7.9532 |
| Lactate dehydraogenase, n=59, 63 | 6.119 ± 18.1156 | 3.889 ± 20.4979 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| 10^9 cells per liter (GI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Basophils, n=58, 63 | -0.003 ± 0.0131 | -0.006 ± 0.0165 |
| Eosinophils, n=58, 63 | -0.019 ± 0.1254 | -0.033 ± 0.1309 |
| Lymphocytes, n=58, 63 | -0.047 ± 0.4096 | -0.206 ± 0.5930 |
| Monocytes, n=58, 63 | -0.033 ± 0.1094 | -0.059 ± 0.1324 |
| Segmented neutrophils, n=58, 63 | 0.114 ± 1.3382 | -0.213 ± 1.0934 |
| Total neutrophils, n=58, 63 | 0.114 ± 1.3382 | -0.213 ± 1.0934 |
| Platelet count, n=58, 63 | 1.621 ± 31.7881 | -6.190 ± 35.7874 |
| White blood cell count, n=58, 63 | 0.014 ± 1.4026 | -0.517 ± 1.2003 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Micromole/liter (UMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Direct bilirubin, n=60, 63 | 0.300 ± 1.0301 | 0.222 ± 1.1974 |
| Indirect bilirubin, n=60, 63 | 1.567 ± 3.4757 | 0.508 ± 3.5372 |
| Total bilirubin, n=60, 63 | 1.867 ± 3.8947 | 0.730 ± 3.8404 |
| Creatinine, n=60, 63 | 2.037 ± 6.4916 | 0.940 ± 5.1644 |
| Uric acid, n=60, 63 | 11.500 ± 38.9622 | 0.159 ± 40.9757 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Millimole/Liter (MMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Calcium (corrected), n=1, 1 | 0.110 ± NA | 0.000 ± NA |
| Calcium, n=59, 63 | -0.020 ± 0.0890 | 0.002 ± 0.0768 |
| Chloride, n=60, 63 | -0.200 ± 2.2981 | 0.444 ± 2.3264 |
| Glucose, n=60, 63 | -0.873 ± 2.5458 | -0.567 ± 1.2118 |
| Potassium, n=59, 63 | 0.000 ± 0.3900 | 0.060 ± 0.3476 |
| Magnesium, n=60, 63 | 0.004 ± 0.0585 | 0.009 ± 0.0462 |
| Sodium, n=60, 63 | -0.400 ± 2.1249 | 0.095 ± 1.9486 |
| Phosphorus inorganic, n=60, 63 | -0.072 ± 0.1505 | -0.063 ± 0.1695 |
| Triglycerides, n=60, 63 | -0.166 ± 0.7155 | -0.156 ± 0.6119 |
| Urea/BUN, n=60, 63 | -0.258 ± 1.1878 | -0.119 ± 1.4134 |
| VLDL cholesterol calculation, n=59, 63 | -0.098 ± 0.2844 | -0.072 ± 0.2810 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Proportion of RBCs in blood | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Hematocrit at Month 6 | 0.009 ± 0.0196 | 0.013 ± 0.0196 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Picograms (PG)/cell | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Mean Corpuscle Hemoglobin at Month 6 | 0.068 ± 0.7111 | 0.146 ± 0.6696 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Femtoliters (FL) | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Mean Corpuscular Volume at Month 6 | 1.695 ± 2.5000 | 2.397 ± 2.6368 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| 10^12 cells per liter (TI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Red Blood Cell Count at Month 6 | 0.025 ± 0.1844 | 0.037 ± 0.1920 |
Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| percentage (%) of mean RBC volume | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Red Cell Distribution Width at Month 6 | 0.475 ± 1.0256 | 0.556 ± 0.9242 |
Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| Participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Diastolic blood pressure, Low, n=60, 63 | 0 | 2 |
| Systolic blood pressure, High, n=60, 63 | 1 | 2 |
| Systolic blood pressure, Low, n=60, 63 | 1 | 1 |
| Heart rate, High, n=60, 63 | 0 | 0 |
| Heart rate, Low, n=60, 63 | 0 | 0 |
Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 6 was summarized.
| Participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Neutralizing antibodies, Positive, n=0, 0 | NA | NA |
| Neutralizing antibodies, Negative, n=0, 0 | NA | NA |
| Binding antibodies, Positive, n=60, 63 | 0 | 0 |
| Binding antibodies, Negative, n=60, 63 | 60 | 63 |
Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.
| Percent change | Denosumab 60 mg to Open-Label Denosumab 60mg |
|---|---|
| Mean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab | 5.62 ± 3.776 |
Mean percent change from Month 6 in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.
| Percent change | Placebo to Open-Label Denosumab 60 mg |
|---|---|
| Mean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo | 2.67 ± 3.440 |
Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.
| Percent change | Denosumab 60 mg to Open-Label Denosumab 60mg |
|---|---|
| Total hip | 3.07 ± 2.476 |
| Femoral neck | 3.39 ± 3.158 |
| Trochanter | 3.39 ± 4.653 |
Mean percent change from Month 6 in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.
| Percent change | Placebo to Open-Label Denosumab 60 mg |
|---|---|
| Total hip | 1.46 ± 1.701 |
| Femoral neck | 1.12 ± 2.668 |
| Trochanter | 2.13 ± 2.762 |
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.
| Percent change | Denosumab 60 mg to Open-Label Denosumab 60mg |
|---|---|
| s-CTx | -63.36 (-77.14 to -48.62) |
| s-PINP | -78.00 (-84.31 to -66.67) |
Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by measure at Month 6 \* 100.
| Percent change | Placebo to Open-Label Denosumab 60 mg |
|---|---|
| s-CTx | -50.90 (-71.95 to -24.05) |
| s-PINP | -66.67 (-76.82 to -55.65) |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
| Participants | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Any AE | 22 | 29 |
| Any SAE | 1 | 3 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Ratio | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Albumin/globulin ratio, n=58, 60 | 0.016 ± 0.1473 | 0.032 ± 0.1621 |
| BUN/creatinine ratio, n=58, 60 | -5.776 ± 24.4297 | 2.500 ± 27.7962 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Grams (G)/Liter (L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Albumin, n=58, 60 | 0.293 ± 2.1110 | 0.450 ± 1.9866 |
| Hemoglobin, n=56, 60 | 1.411 ± 5.7833 | 2.033 ± 6.0084 |
| Mean corpuscle hemoglobin concentration, n=56, 60 | -5.679 ± 6.6143 | -6.650 ± 7.7587 |
| Total protein, n=58, 60 | 0.224 ± 3.4946 | 0.267 ± 2.8216 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Internationational Units(IU)/Liter (L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Alkaline phosphatase, n=58, 60 | -25.603 ± 14.4780 | -23.767 ± 15.7570 |
| Alanine amino transferase, n=58, 60 | 1.810 ± 7.9922 | -0.150 ± 8.9288 |
| Aspartate amino transferase, n=58, 60 | 0.879 ± 6.4293 | -0.467 ± 6.2666 |
| Creatine kinase, n=58, 60 | -4.534 ± 44.0690 | 4.500 ± 52.0731 |
| Gamma glutamyl transferase, n=58, 60 | 0.4823 ± 6.9541 | -0.600 ± 9.4961 |
| Lactate dehydraogenase, n=58, 60 | -0.552 ± 19.2237 | -1.217 ± 24.7243 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| 10^9 cells per liter (GI/L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Basophils, n=54, 59 | -0.004 ± 0.0164 | -0.002 ± 0.0148 |
| Eosinophils, n=54, 59 | 0.024 ± 0.1489 | 0.019 ± 0.1860 |
| Lymphocytes, n=54, 59 | 0.098 ± 0.4436 | -0.089 ± 0.5599 |
| Monocytes, n=54, 59 | -0.009 ± 0.1053 | -0.039 ± 0.1443 |
| Segmented neutrophils, n=54, 59 | 0.014 ± 1.1748 | -0.259 ± 1.2035 |
| Total neutrophils, n=54, 59 | 0.014 ± 1.1748 | -0.259 ± 1.2035 |
| Platelet count, n=55, 60 | -4.018 ± 34.8215 | -4.233 ± 37.7913 |
| White blood cell count, n=54, 59 | 0.122 ± 1.1618 | -0.369 ± 1.3903 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Micromole/liter (UMOL/L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Direct bilirubin, n=58, 60 | 0.241 ± 1.3548 | 0.100 ± 1.2980 |
| Indirect bilirubin, n=58, 60 | 1.034 ± 4.0391 | 0.800 ± 3.3385 |
| Total bilirubin, n=58, 60 | 1.276 ± 4.6596 | 0.900 ± 3.5401 |
| Creatinine, n=58, 60 | 0.948 ± 5.1157 | -0.015 ± 4.6216 |
| Uric acid, n=58, 60 | 4.483 ± 41.3870 | 2.000 ± 44.0647 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Millimole/Liter (MMOL/L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Calcium (corrected), n=0, 0 | NA ± NA | NA ± NA |
| Calcium, n=58, 60 | -0.031 ± 0.0944 | -0.004 ± 0.0904 |
| Chloride, n=58, 60 | 0.328 ± 2.5573 | 0.300 ± 2.4446 |
| Glucose, n=58, 60 | -0.760 ± 2.9331 | -0.500 ± 1.2985 |
| Potassium, n=58, 60 | 0.047 ± 0.4398 | 0.045 ± 0.3078 |
| Magnesium, n=58, 60 | 0.009 ± 0.0679 | 0.004 ± 0.0514 |
| Sodium, n=58, 60 | -0.172 ± 2.1532 | 0.067 ± 2.2986 |
| Phosphorus inorganic, n=58, 60 | -0.153 ± 0.1530 | -0.094 ± 0.1981 |
| Triglycerides, n=58, 60 | -0.144 ± 0.7716 | -0.033 ± 0.8449 |
| Urea/BUN, n=58, 60 | -0.233 ± 1.2183 | 0.158 ± 1.5771 |
| VLDL cholesterol calculation, n=58, 59 | -0.066 ± 0.3539 | -0.044 ± 0.3234 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Proportion of RBCs in blood | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Change From Baseline in Hematocrit at Month 12 | 0.010 ± 0.0182 | 0.014 ± 0.0185 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Picograms (PG)/cell) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Change From Baseline in Mean Corpuscle Hemoglobin at Month 12 | -0.304 ± 0.7632 | -0.310 ± 0.5058 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| 10^12 cells per liter (TI/L) | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Change From Baseline in Red Blood Cell Count at Month 12 | 0.086 ± 0.1634 | 0.103 ± 0.1904 |
Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| percentage (%) of mean RBC volume | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Change From Baseline in Red Cell Distribution Width at Month 12 | 0.007 ± 0.7897 | 0.203 ± 0.8718 |
Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 12 value minus the Baseline value.
| Participants | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Diastolic blood pressure, High | 0 | 1 |
| Diastolic blood pressure, Low | 2 | 0 |
| Systolic blood pressure, High | 0 | 2 |
| Systolic blood pressure, Low | 0 | 2 |
| Heart rate, High | 0 | 0 |
| Heart rate, Low | 0 | 0 |
Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 12 was summarized.
| Participants | Denosumab 60 mg to Open-Label Denosumab 60mg | Placebo to Open-Label Denosumab 60 mg |
|---|---|---|
| Neutralizing antibodies, Positive, n=0, 0 | NA | NA |
| Neutralizing antibodies, Negative, n=0, 0 | NA | NA |
| Binding antibodies, Positive, n=58, 61 | 0 | 0 |
| Binding antibodies, Negative, n=58, 61 | 58 | 61 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the end of the Open-Label Phase (up to Month 12).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase: Denosumab 60 mg | — | 7/69 (10.1%) | 13/69 (18.8%) |
| Randomized Phase: Placebo | — | 2/66 (3%) | 11/66 (16.7%) |
| Open Label Denosumab 60 mg (Previously Randomized Denosumab) | — | 1/60 (1.7%) | 12/60 (20%) |
| Open Label Denosumab 60 mg (Previously Randomized Placebo) | — | 3/63 (4.8%) | 7/63 (11.1%) |
| Event | Randomized Phase: Denosumab 60 mg | Randomized Phase: Placebo | Open Label Denosumab 60 mg (Previously Randomized Denosumab) | Open Label Denosumab 60 mg (Previously Randomized Placebo) |
|---|---|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/69 | 0/66 | 0/60 | 0/63 |
| Macular holeEye disorders | 0/69 | 0/66 | 1/60 | 0/63 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/69 | 0/66 | 0/60 | 1/63 |
| Appendicitis perforatedInfections and infestations | 0/69 | 0/66 | 0/60 | 1/63 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/69 | 0/66 | 0/60 | 1/63 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/69 | 1/66 | 0/60 | 0/63 |
| AppendicitisInfections and infestations | 0/69 | 1/66 | 0/60 | 0/63 |
| BronchitisInfections and infestations | 1/69 | 0/66 | 0/60 | 0/63 |
| HaemorrhoidsGastrointestinal disorders | 1/69 | 0/66 | 0/60 | 0/63 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/69 | 0/66 | 0/60 | 0/63 |
| Event | Randomized Phase: Denosumab 60 mg | Randomized Phase: Placebo | Open Label Denosumab 60 mg (Previously Randomized Denosumab) | Open Label Denosumab 60 mg (Previously Randomized Placebo) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/69 | 8/66 | 6/60 | 6/63 |
| ConstipationGastrointestinal disorders | 5/69 | 2/66 | 0/60 | 0/63 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/69 | 1/66 | 0/60 | 0/63 |
| DyspepsiaGastrointestinal disorders | 0/69 | 0/66 | 3/60 | 1/63 |
| GastritisGastrointestinal disorders | 0/69 | 0/66 | 3/60 | 0/63 |
| Ligament sprainInjury, poisoning and procedural complications | 0/69 | 0/66 | 3/60 | 1/63 |
| Age, Continuous(Years) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Mean | 67.0 ± 4.86 | 66.0 ± 4.77 | 66.5 ± 4.83 |
| Sex: Female, Male(Participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Female | 69 | 66 | 135 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 69 | 66 | 135 |
The record gives a start of Nov 2011, a primary completion of Dec 2012 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →